You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx)

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx)

 

Online download statistics by month:

Online download statistics by month: October 2020 to May 2022

AbstractFullPdf
Oct 202026126176
Nov 202018118052
Dec 2020878733
Jan 2021747437
Feb 2021303020
Mar 2021505023
Apr 2021535342
May 2021494921
Jun 2021393817
Jul 2021414110
Aug 2021333319
Sep 2021323214
Oct 2021727250
Nov 2021545544
Dec 2021454620
Jan 2022373819
Feb 2022313330
Mar 2022424316
Apr 2022414317
May 2022505122
Total13021309582